New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer
Full article:

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.  

The following studies are looking at treatment for people with advanced solid tumors. 



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.